Autopsy report · NCT02396251

Evaluation of Efficacy and Safety of Hyaluronic Acid (HA) Product for Cheek Augmentation

“Sponsor business reasons”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 9 months before it stopped.
• 48 participants enrolled.
• Results were posted on the registry 1 year 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Galderma R&D

Sponsor type

Industry

Conditions

Facial Tissue Augmentation

Interventions

HA experimental; HA comparator

Participants

48

Sites

2

Countries

Sweden

Trials that died the same way

• Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
  “Sponsor business considerations” (88% match in meaning)
• Novum Vitrium® Cervical Cage in Anterior Cervical Discectomy and Fusion
  “Sponsor business decision” (82% match in meaning)
• Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
  “Sponsor's business decision” (82% match in meaning)
• BST-DERMON Versus Standard of Care in the Treatment of Diabetic Foot Ulcers
  “Due to Sponsor's financial reasons” (79% match in meaning)
• Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker
  “business decision by sponsor” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.